UBS Group AG Purchases New Holdings in Medline $MDLN

Key Points

• UBS Group AG bought a new Q4 stake in Medline (NASDAQ:MDLN), acquiring 1,302,548 shares worth about $54,707,000 and owning roughly 0.10% of the company at quarter-end.
• Other institutions also opened large positions in Q4, most notably Massachusetts Financial Services (~$429.5M) and Baillie Gifford & Co. (~$437.2M), indicating substantial institutional interest.
• Medline’s 12‑month trading range is $34.89–$50.88, and analysts hold a consensus "Moderate Buy" rating with an average price target of $50.62.

UBS Group AG purchased a new stake in Medline (NASDAQ:MDLN - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,302,548 shares of the company's stock, valued at approximately $54,707,000. UBS Group AG owned 0.10% of Medline at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in MDLN. Perigon Wealth Management LLC acquired a new position in Medline during the fourth quarter worth about $211,000. SteelPeak Wealth LLC bought a new position in shares of Medline in the 4th quarter valued at $441,000. Sound Income Strategies LLC bought a new position in shares of Medline in the 4th quarter valued at $25,000. Massachusetts Financial Services Co. MA bought a new position in shares of Medline in the 4th quarter valued at $429,544,000. Finally, Baillie Gifford & Co. bought a new position in shares of Medline in the 4th quarter valued at $437,236,000.

Get Medline SMS alerts:

Sign Up

Medline Price Performance

Shares of NASDAQ:MDLN opened at $45.32 on Wednesday. Medline has a 12-month low of $34.89 and a 12-month high of $50.88. The stock's fifty day moving average is $44.72.

Medline (NASDAQ:MDLN - Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter. The company had revenue of $7.35 billion for the quarter. Analysts expect that Medline will post 1.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MDLN has been the subject of a number of research reports. BTIG Research reiterated a "buy" rating and issued a $55.00 price target on shares of Medline in a research note on Monday, March 9th. BNP Paribas Exane initiated coverage on Medline in a research note on Monday, January 12th. They issued a "neutral" rating and a $38.00 price target for the company. Royal Bank Of Canada increased their price target on Medline from $47.00 to $53.00 and gave the company an "outperform" rating in a research note on Thursday, February 26th. Citigroup initiated coverage on shares of Medline in a report on Wednesday, March 11th. They set a "buy" rating and a $60.00 target price on the stock. Finally, JPMorgan Chase & Co. boosted their target price on shares of Medline from $50.00 to $53.00 and gave the stock an "overweight" rating in a report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $50.62.

About Medline

Medline NASDAQ: MDLN is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

Want to see what other hedge funds are holding MDLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medline (NASDAQ:MDLN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.